Infliximab is a chimeric immunoglobulin (IgG 1 Kappa) targeting TNF-alpha molecules. It is an FDA approved therapeutic agents for multiple inflammatory conditions like Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis and Rheumatoid Arthritis. The trough concentration of these drugs can vary due to disease severity, phenotype, and degree of inflammation, use of immunomodulatory, patient gender and body mass index, as well as variability in drug clearance through immune and non-immune mediated mechanisms. Several studies have demonstrated that infliximab quantitation in the setting of loss of response to therapy can aid in patient management, as trough concentrations defined as therapeutic have been associated with superior clinical response and improved prognosis.

  • Test Type:
  • Pre-test Information:
  • Report Delivery:
    Sample by Fri 9 am; Report Same day
  • Components: